Abstract
e14559Background: Copanlisib, an iv pan-PI3K inhibitor recently approved for treatment of relapsed follicular lymphoma, is metabolized by CYP3A4 ( > 90%) in vitro. Here, we report effects of rifamp...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
